Elevance Health (ELV) recently highlighted new capabilities in its Health OS platform, connecting directly with electronic health records and Epic’s Payer Platform to simplify clinical review, prior authorization, and care coordination for providers and members.

These Health OS upgrades come as Elevance Health’s share price sits at US$395.10, with a 90-day share price return of 33.44% and a 1-year total shareholder return of 7.17%. The 3-year total shareholder return shows a decline of 6.64%, indicating improving recent momentum after a weaker multi year stretch.

If you are weighing Elevance Health alongside other healthcare technology stories, this is a good moment to look at companies using AI in care delivery and operations through the 38 healthcare AI stocks

With Elevance Health trading at US$395.10 after a strong 90 day run, the key question is whether the Health OS and digital programs are already fully reflected in the valuation, or whether the recent momentum still leaves a genuine opportunity that markets have not fully priced in.

Most Popular Narrative: 2% Overvalued

Compared with the narrative fair value estimate of $387.85, Elevance Health’s last close at $395.10 sits modestly above that mark, which frames how analysts are thinking about the stock’s risk and reward trade off.

Analysts are assuming Elevance Health's revenue will grow by 6.8% annually over the next 3 years.

Analysts assume that profit margins will increase from 2.8% today to 3.2% in 3 years time.

The fair value hinges on a specific earnings roadmap, steady margin rebuild, and a future valuation multiple below many peers. Want to see exactly how those pieces fit together?

Result: Fair Value of $387.85 (OVERVALUED)

However, Elevance Health still faces real pressure from elevated medical cost trends and shifting Medicare Advantage and ACA policies, which could cap margins and challenge the current narrative.

Another View: Elevance Health Through Earnings Multiples

While the narrative fair value puts Elevance Health at $387.85 and labels the stock as modestly overvalued at $395.10, the earnings multiple story points in a different direction. A current P/E of 16.4x is described as good value versus both a 30.7x fair ratio and a 23.1x industry average, with peers around 38.6x. For investors, that gap raises a simple question: is the market underpricing Elevance Health’s earnings power or correctly discounting policy and growth risks?

Next Steps

If the mixed signals around Elevance Health have you on the fence, act while the data is fresh and weigh the company’s strengths for yourself through the 4 key rewards

Looking for more investment ideas beyond Elevance Health?

Elevance Health may be on your radar today, but you do not want to stop there when other compelling stock ideas are just a few clicks away.

• Target dependable cash generation with companies that pair quality earnings with attractive pricing through the 44 high quality undervalued stocks
• Strengthen your income stream by focusing on businesses built around robust, higher yielding payouts using the 7 dividend fortresses
• Prioritise resilience by scanning for companies that score well on stability and risk through the 67 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.